Skip to main content

Management

 
Anna Ljung, CEO , M.Sc. Econ.

Born 1980. Active in the company since 2006. Anna Ljung has more than 15 years of experience in the pharmaceutical industry, including as CFO of other biotech companies such as Athera Biotechnologies AB and Lipopetide AB and as independent technology licensing consultant. In addition to serving as CEO of Moberg Pharma, she also currently serves as Board member of Saniona AB and ADDvise Group AB.

Shareholding: 24 033 shares and 450 000 performance share units that can entitle a maximum of 379 846 shares.

 

Anders Bröijersén, CMO, MD, PhD

Born 1964. Active in the company since 2023. Anders Bröijersén is board certified in internal medicine and has a PhD from the department of Clinical Pharmacology at the Karolinska University Hospital. Anders has more than 15 years of experience from the pharmaceutical industry with leading positions within Medical Affairs, Clinical Development and Pharmacovigilance in companies such as Sobi, Boehringer-Ingelheim, MSD and InDex Pharmaceuticals.  

Shareholding: 1 533 shares and 30 000 performance share units that can entitle a maximum of 82 958 shares.

Annica Magnusson, Senior Director of Regulatory Affairs

Born in 1963. Has worked for the company since 2013. Annica Magnusson is a pharmacist with more than 20 years of experience in international work within the pharmaceutical industry and Regulatory Affairs at AstraZeneca. Annica Mangusson has worked with the development and registration of pharmaceuticals, vaccines and medical devices in the EU, USA, Japan with several markets.

Shareholding: 873 shares and 430 000 performance share units that can entitle a maximum of 324 541 shares.

 

Mark Beveridge, Vice President Finance

Born 1978. B. Com, GradDipCA. Active in the company since 2015. Mark Beveridge has more than 15 years of experience as an advisor in accounting, insurance and auditing, primarily from Crowe Horwath and Visma Services. Mark has also worked as an independent consultant within financial control, transaction consultancy and implementation of business systems. Mark is Board member of Loaded Dice AB.

Shareholding: 43 158 shares and 430 000 performance share units that can entitle a maximum of 324 541 shares.


Christina Erixon, Head of Pharmaceutical Development & Operations

Born 1970. Dr Erixon has a broad experience of development, regulatory and quality within the pharmaceutical industry. She has held leading positions within the pharmaceutical industry and at regulatory authorities, including roles as manager of clinical trials at the Swedish Medical Products Agency, senior product developer at AstraZeneca, business manager and associate director Pharmaceutical Development at APL, and most recently as the director of Drug Development at SDS Life Science. Dr. Erixon is a pharmacist with a doctoral degree in pharmaceutics from Uppsala University.

Shareholding: 0 shares and 0 performance share units

Robert Ehrl, Head of Supply

Born 1967. Active in the company since 2023. Robert Ehrl holds a PhD in organic chemistry with over 20 years of broad experience in the pharmaceutical industry. Robert has held leadership positions at AstraZeneca and Valneva Sweden AB, mainly within process development, supply, and manufacturing. He has worked with both small molecule and biological drugs/vaccines, from API to prepackaged product.

Shareholding: 0 shares and 0 performance share units

Current shareholding is not automatically updated for the moment. Insiders no longer have obligation to report there shareholding. According to the regulatory requirements, the data shall be updated once a year.